Business
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the Boards of Directors of both companies and Amicus' Board of Directors unanimously recommended that Amicus' stockholders vote to adopt the agreement. The transaction is expecte
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters","length":237,"tagName":"p","attribs":{}},{"type":"text","content":"Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin's Global Footprint; Pending U.S. Galafold Patent Litigation Resolved","length":189,"tagName":"p","attribs":{}},{"type":"text","content":"Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027","length":229,"tagName":"p","attribs":{}},{"type":"text","content":"Conference Call Today at 8:15 a.m. Eastern Time ","length":52,"tagName":"p","attribs":{}},{"type":"text","content":"SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the Boards of Directors of both companies and Amicus' Board of Directors unanimously recommended that Amicus' stockholders vote to adopt the agreement. The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.","length":733,"tagName":"p"},{"type":"image","alt":"BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)","displaySize":"","headline":null,"caption":"BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":59,"url":"https://media.zenfs.com/en/prnewswire.com/db94610f2d68c7fd655942d2889db5d2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KxRqzB62ez2RdMQaPUuMVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/db94610f2d68c7fd655942d2889db5d2","width":400,"height":59}},"href":"https:...